Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02773238 | FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging | completed | Phase 2 | 51 | University of WashingtonOTHER | 1 | Aug 14, 2024 |
| NCT04529564 | Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA) | completed | — | 106 | AstraZenecaINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03371485 | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Cancer Research UKOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04144608 | Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC(TOGATHER) | completed | Phase 2 | 40 | Yongchang ZhangOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05068427 | Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | completed | Phase 2 | 34 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05634551 | Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status | completed | — | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01712217 | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | completed | Phase 1 / Phase 2 | 220 | Astex Pharmaceuticals, Inc.INDUSTRY | 5 | Aug 2, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT03689855 | Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC(RamAtezo-1) | completed | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06521034 | First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer(Helpful) | completed | Phase 1 / Phase 2 | 124 | Yongchang ZhangOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03819387 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | completed | Phase 1 | 49 | Nitto BioPharma, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06516796 | Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size | completed | — | 2,713 | Liang ChenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT03485326 | A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | completed | — | 1,700 | AstraZenecaINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04194203 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | completed | Phase 3 | 305 | Hoffmann-La RocheINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT04732520 | Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer(INCITE ES) | completed | N/A | 47 | Galvanize Therapeutics, Inc.INDUSTRY | 3 | Jul 19, 2024 | clinicaltrials |
| NCT03195491 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia(CheckMate870) | completed | Phase 3 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 18, 2024 | clinicaltrials |
| NCT03560791 | A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence(REACH) | completed | — | 7,659 | St Elizabeth HealthcareOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04207775 | Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy(PISCES) | completed | — | 300 | AstraZenecaINDUSTRY | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03091816 | Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer | completed | — | 15 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03681483 | RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT00254384 | Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery | completed | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06378658 | A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants | completed | Phase 1 | 21 | BayerINDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06360211 | A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants | completed | Phase 1 | 15 | BayerINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT01513174 | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone(GOAL) | completed | Phase 1 / Phase 2 | 186 | Spanish Lung Cancer GroupOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06221475 | A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants | completed | Phase 1 | 8 | BayerINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04740047 | Cios Mobile 3D Spin for Robotic Bronchoscopy | completed | — | 38 | Mayo ClinicOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06232967 | PPIO-006 Primary Tumor Resection for IVa NSCLC | completed | — | 223 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06294561 | TGRX-326 Pharmacokinetic Drug Interaction | completed | Phase 1 | 34 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 7 | Jun 26, 2024 | clinicaltrials |
| NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 8 | Jun 26, 2024 | clinicaltrials |
| NCT04642469 | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.(MERMAID-2) | completed | Phase 3 | 30 | AstraZenecaINDUSTRY | 25 | Jun 25, 2024 | clinicaltrials |
| NCT03693300 | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 117 | AstraZenecaINDUSTRY | 6 | Jun 18, 2024 | clinicaltrials |
| NCT03950674 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | completed | Phase 3 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03847519 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 24 | Advaxis, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03497767 | A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases(OUTRUN) | completed | Phase 2 | 40 | Trans Tasman Radiation Oncology GroupOTHER | 2 | May 31, 2024 | clinicaltrials |
| NCT03022500 | Pulmonary sarcomatoid_MEDI4736+Treme | completed | Phase 2 | 32 | Seoul National University HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04426825 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 15, 2024source: clinicaltrials